Table of Contents
Introduction: A New Angle on Recovery
Semaglutide is a medicine that many people know because it helps treat type 2 diabetes and obesity. You may have heard of it under brand names like Ozempic or Wegovy. It works by mimicking a natural hormone in the body called GLP-1, which helps control blood sugar and hunger. But now, researchers are finding that semaglutide might also do something unexpected—it could help people who are struggling with addiction.
This discovery is opening new doors in science and medicine. Addiction, also called substance use disorder (SUD), is a serious condition. It affects the brain and behavior. People with SUD often find it very hard to stop using drugs or alcohol, even when it causes harm in their lives. For many years, doctors have been trying to find better ways to treat addiction. The usual treatments include therapy and medicines that help reduce cravings or block the effects of certain drugs. But not everyone responds to these treatments, and relapse (going back to drug use) is very common.
In recent years, scientists have started looking more closely at how drugs like semaglutide affect the brain. What they have found is surprising. It turns out that the same hormone system that helps control hunger might also play a role in how we respond to rewards like drugs and alcohol. This means that medicines like semaglutide might help change the way the brain reacts to addictive substances.
Animal studies were the first to show this connection. When researchers gave semaglutide or other similar drugs to rats and mice, the animals seemed to lose interest in alcohol, cocaine, and other addictive substances. Some even stopped seeking the substances altogether. These early results got researchers wondering if semaglutide could work the same way in people.
Now, some early studies in humans are starting to take place. Scientists are testing whether semaglutide can reduce cravings, stop drug-seeking behavior, or prevent relapse. These studies are still new, and we do not have all the answers yet. But the results so far are promising enough that addiction experts are paying close attention.
One reason this is so important is because addiction is not just a problem of willpower. It changes the brain’s reward system in deep ways. People with addiction often have trouble feeling pleasure from normal things like food, relationships, or hobbies. Their brains become wired to seek out drugs or alcohol, even when they don’t want to. This is why treatments that target the brain directly are so important. Semaglutide may be one of those treatments.
Also, many people with substance use disorders have other health problems too. They may have diabetes, obesity, or heart disease. These conditions can make recovery harder. Semaglutide may be helpful here because it can also improve blood sugar, support weight loss, and lower inflammation. This means it might offer more than one kind of benefit for people in recovery.
This article will explore the growing link between semaglutide and substance use disorder research. We will answer the most common questions people ask about these topics. We’ll look at how semaglutide works, how it affects the brain, what studies are being done, and what risks and challenges still exist. While this is a new and developing field, the science behind it is real and growing fast.
By the end of this article, you will have a clear understanding of how semaglutide could one day change the way we think about addiction treatment. This is not just about a weight-loss drug—it’s about the way medicine and science are finding new paths to recovery, based on how the body and brain work together.
What Is Semaglutide? Understanding the Mechanism of Action
Semaglutide is a type of medicine that was first made to help people with type 2 diabetes. Doctors now also use it to help people lose weight. It works by copying a hormone in your body called GLP-1, which stands for glucagon-like peptide-1. This hormone helps control blood sugar levels, hunger, and how full you feel after eating.
How Semaglutide Works in the Body
When you eat food, your body releases GLP-1 from your intestines. This hormone has several important jobs. First, it helps your pancreas release insulin. Insulin is a hormone that lowers blood sugar by helping it move from your blood into your cells. GLP-1 also lowers the amount of another hormone called glucagon, which raises blood sugar. When these two effects happen together, blood sugar levels stay more balanced.
Semaglutide acts like GLP-1 but stays in the body much longer. That means it works over time instead of wearing off quickly like your body’s natural GLP-1. It is called a GLP-1 receptor agonist. This means it sticks to the same spots in the body as natural GLP-1 and turns them on to create the same effects.
Semaglutide is given as a shot once a week. A newer version is also available as a daily pill. Once in your body, it helps with blood sugar control, but it also slows down how quickly food leaves your stomach. This makes you feel full for a longer time and helps reduce appetite.
FDA-Approved Uses of Semaglutide
In the United States, the Food and Drug Administration (FDA) has approved semaglutide for two main reasons:
- Type 2 Diabetes: Semaglutide helps lower blood sugar levels in people who have this disease. It is often used when other treatments, like metformin, are not enough.
- Chronic Weight Management: Some forms of semaglutide are used to help adults with obesity or people who are overweight and also have other health problems, like high blood pressure or high cholesterol. It helps reduce hunger and helps people lose weight.
Semaglutide is sold under brand names like Ozempic, Wegovy, and Rybelsus. Ozempic and Rybelsus are usually for diabetes, while Wegovy is mostly for weight loss.
Effects on the Brain
While semaglutide was made for blood sugar and weight problems, scientists noticed something interesting. It also affects the brain. The GLP-1 hormone, and drugs like semaglutide, can reach areas in the brain that control hunger, pleasure, and reward. These are the same parts of the brain linked to addiction.
When semaglutide reaches these brain areas, it can lower the signals that make people feel strong cravings. This is why researchers are now studying it for conditions like substance use disorder (SUD). It may help reduce the desire to use drugs or alcohol, similar to how it helps reduce food cravings.
Semaglutide’s Effects on Behavior
Some people using semaglutide have said they feel less interested in food, alcohol, or even certain habits like smoking. Scientists believe this may be because of how the drug changes activity in brain circuits related to motivation and reward. These are the same brain systems involved when someone develops an addiction.
Early animal studies support this idea. For example, rats given semaglutide showed less interest in drinking alcohol or using drugs like cocaine. These findings are exciting, but more research is needed in people to know how strong these effects are and who might benefit most.
Semaglutide is a medicine that copies the effects of a natural hormone called GLP-1. It helps control blood sugar, reduces hunger, and helps people lose weight. It does this by working in the body and the brain. Because of how it affects the brain, scientists are now studying semaglutide to see if it can also help people with substance use disorders. It may help reduce cravings and support recovery. Though more research is needed, semaglutide is offering new hope beyond its original purpose.
What Are Substance Use Disorders? A Clinical Overview
Substance use disorders, often called SUDs, happen when a person cannot stop using a drug or alcohol, even though it is causing harm. This condition affects the brain and behavior. It is not just about bad habits or poor choices. It is a medical condition that can change how the brain works over time.
People with SUDs may feel strong urges, or cravings, to use drugs or alcohol. They may lose control over how much or how often they use. Many also keep using even when it hurts their health, relationships, work, or school.
Understanding Substance Use Disorders
Doctors and mental health experts use a guide called the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) to diagnose mental health conditions, including SUDs. According to the DSM-5, there are 11 signs used to diagnose a substance use disorder. These include:
- Taking the substance in larger amounts or for longer than planned
- Wanting to cut down but not being able to
- Spending a lot of time getting, using, or recovering from the substance
- Having strong cravings
- Failing to do important tasks at work, school, or home
- Continuing to use, even when it causes problems in relationships
- Giving up activities you used to enjoy
- Using in dangerous situations, like while driving
- Continuing to use even when it causes health problems
- Needing more of the substance to get the same effect (tolerance)
- Having withdrawal symptoms when not using
If a person shows two or more of these signs within a year, they may be diagnosed with a substance use disorder. The more signs a person has, the more severe the disorder.
Common Substances Involved in SUDs
Many types of substances can lead to addiction. Some of the most common include:
- Alcohol: One of the most widely used substances. It can lead to liver damage, heart problems, and brain changes.
- Opioids: These include prescription painkillers like oxycodone and illegal drugs like heroin. Opioids are highly addictive and can cause life-threatening overdoses.
- Stimulants: Drugs like cocaine, methamphetamine, and some ADHD medications. They can cause heart problems, anxiety, and sleep issues.
- Cannabis: While legal in some areas, heavy use can still lead to problems with memory, mood, and learning.
- Nicotine: Found in cigarettes and vapes, nicotine is also addictive and linked to cancer, lung disease, and heart problems.
- Benzodiazepines: These drugs are used for anxiety or sleep, but they can be addictive if used long-term.
Each drug affects the brain in different ways, but many act on the brain’s reward system. This system releases a chemical called dopamine. Dopamine makes you feel pleasure. When a drug causes a large release of dopamine, the brain remembers the feeling and wants to repeat it. Over time, this can lead to addiction.
How Addiction Affects the Brain
SUDs can change how the brain works. The brain begins to expect the drug to feel “normal.” This change affects self-control, decision-making, and emotional balance. People may feel anxious, sad, or angry when they do not use the drug. They may also struggle to feel joy from normal life activities.
These brain changes do not go away right after stopping the drug. That is why recovery can be hard. People may relapse, or start using again, even after treatment. This does not mean treatment failed — it means the brain needs more time to heal.
Current Treatments for Substance Use Disorders
Treatments for SUDs often combine medicine, counseling, and support. This is called a “whole-person” approach. Some medicines can help with cravings or withdrawal symptoms. Others block the effects of drugs or make people sick if they use the drug again. Examples include:
- Methadone or buprenorphine for opioid addiction
- Naltrexone for alcohol or opioid addiction
- Nicotine replacement therapy for tobacco use
Therapy also plays a big role. Cognitive behavioral therapy (CBT) helps people learn new ways to deal with stress and triggers. Support groups, like 12-step programs, give people a place to share their journey and find strength in others.
But even with these tools, not all people respond the same. Some drugs do not work for every type of addiction. That is why researchers are always looking for better ways to treat SUDs — including studying new medicines like semaglutide.
Substance use disorders are complex, but they are treatable. Understanding how they work is the first step toward helping more people recover.
How Did Semaglutide Become Linked to Addiction Research?
Semaglutide was first created to help people with type 2 diabetes. Later, it was also approved to help with weight loss in people who are overweight or have obesity. Doctors noticed that people taking semaglutide often reported fewer cravings for food, especially for sugary or high-fat foods. Some people also said they felt less interested in alcohol or smoking. These early observations led scientists to wonder: Could semaglutide affect the brain in a way that also helps with addiction?
To understand how this connection started, it helps to look at how semaglutide works. Semaglutide is part of a group of drugs called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1, which is a hormone that helps control blood sugar and appetite. But GLP-1 also affects the brain, especially the parts involved in decision-making, emotions, and rewards.
The reward system in the brain helps us feel pleasure. It is also the part of the brain involved in addiction. Drugs like alcohol, nicotine, cocaine, and opioids increase the release of a brain chemical called dopamine. Dopamine is sometimes called the “feel-good” chemical. When dopamine levels rise, a person feels pleasure. Over time, the brain starts to expect this dopamine boost from the drug, which can lead to cravings and addiction.
Researchers discovered that GLP-1 receptors are found in the same brain areas that are involved in the reward system. These areas include the nucleus accumbens and the ventral tegmental area (VTA), which play a big role in how the brain responds to rewards. This led scientists to test GLP-1 drugs, like semaglutide, to see if they might change the way the brain responds to addictive substances.
Early research began with animal studies. In these studies, rats or mice were given semaglutide or other GLP-1 drugs. Then, the animals were tested with addictive substances like alcohol, nicotine, or cocaine. The scientists measured how much of the drug the animals chose to take. In many cases, the animals that received semaglutide showed less interest in the drug. They drank less alcohol or took fewer doses of nicotine or cocaine compared to animals that did not receive the GLP-1 drug. This suggested that semaglutide may reduce drug-seeking behavior.
Other studies looked at brain activity. In animals that received semaglutide, the reward centers in the brain were less active when exposed to addictive substances. There was also less dopamine released, which may explain why the animals were less motivated to take the drugs. These results were promising and showed that GLP-1 drugs might help treat addiction.
Scientists then began to look for signs of the same effects in humans. Some people taking semaglutide for diabetes or weight loss began reporting that they were drinking less alcohol or smoking fewer cigarettes—even though they weren’t trying to change those habits. These reports were not part of official studies at first, but they caught the attention of researchers. This led to small pilot studies and clinical trials to test the idea more formally in people.
The first human studies are still early, but some show that people taking semaglutide may have fewer cravings for alcohol. Others are testing its effects on people with alcohol use disorder, nicotine addiction, or even opioid dependence. These studies use tools like questionnaires, brain scans, and lab tests to measure changes in craving, drug use, and brain activity.
The growing body of research—starting from animal models and moving to human trials—has helped build a strong case for further investigation. The link between semaglutide and addiction research is now a major topic in neuroscience and addiction medicine. What began as a drug for blood sugar control has turned into a possible tool for helping people recover from substance use disorders.
As scientists continue to study how semaglutide works in the brain, they are learning more about the ways metabolic and mental health are connected. This connection may lead to new treatments that support both physical health and recovery from addiction.
Can Semaglutide Reduce Cravings or Drug-Seeking Behavior?
Semaglutide is mostly known for helping people with type 2 diabetes and obesity. It lowers blood sugar and reduces appetite. But now, scientists are studying it for something very different — helping people with substance use disorders. Early research shows semaglutide might reduce cravings and drug-seeking behavior. This means it could play a role in helping people avoid harmful substances like alcohol, nicotine, opioids, or cocaine.
How Semaglutide Affects the Brain’s Reward System
To understand why semaglutide might help, it’s important to look at how addiction works. When someone uses drugs or alcohol, it triggers a strong release of dopamine in the brain. Dopamine is a chemical that makes people feel pleasure and reward. Over time, the brain gets used to the substance and starts to crave it. This craving is what makes addiction so difficult to treat.
Semaglutide acts on GLP-1 receptors. These are found not only in the pancreas and gut but also in the brain — especially in areas linked to reward, such as the nucleus accumbens and the ventral tegmental area (VTA). These are the same brain regions involved in cravings and pleasure from drugs.
When semaglutide activates GLP-1 receptors in the brain, it seems to change how these reward systems respond. Studies in animals show that GLP-1 receptor agonists like semaglutide can reduce how much pleasure animals get from drugs, and even lower their desire to take them again. This change might be due to a lower dopamine response, which reduces the “high” people usually feel.
What Animal Studies Have Found
Most of the current data comes from animal research. In one study, rats that were given semaglutide pressed a lever less often to get cocaine. This shows they were less motivated to use the drug. Other studies found similar effects with alcohol, nicotine, and opioids.
For example, in a study involving alcohol, rats normally chose to drink alcohol when given the chance. But after receiving semaglutide, they drank much less. Scientists believe the drug reduced the rewarding feeling the rats got from drinking. It didn’t make them sick — they just didn’t want it as much anymore.
These findings are important because they show a pattern. Across different types of drugs, semaglutide seems to lower the desire to keep using. It might make it easier for people to stop or stay in recovery.
What Human Research Is Showing So Far
While animal studies are promising, it’s still early when it comes to people. There are only a few studies looking at semaglutide and substance use in humans. However, some small reports and pilot studies suggest it might help reduce cravings.
In one small study, people who were taking semaglutide for weight loss said they had fewer cravings — not just for food, but also for things like alcohol and cigarettes. This is not enough to prove anything, but it gives scientists a reason to study it more closely.
Other reports suggest that people taking GLP-1 drugs (like semaglutide or liraglutide) may drink less alcohol. These are not controlled trials, so we cannot be sure the drug caused the change. Still, they support what animal studies are showing — that semaglutide might reduce the brain’s urge to seek out rewards from harmful substances.
Why This Could Be a Big Step in Addiction Treatment
Many treatments for substance use focus on managing withdrawal or blocking the effects of the drug. Semaglutide could offer something different. It might make people not want the substance in the first place. That would be a major shift.
By changing how the brain reacts to rewards, semaglutide might help people feel less tempted. If someone feels fewer cravings, it may be easier to avoid relapse. This could be especially helpful when combined with therapy or other support programs.
Right now, we need more studies in humans to know for sure how semaglutide affects cravings. But early research is hopeful. Animal models show it can reduce the drive to seek drugs. Small human studies hint at similar effects.
If future research confirms these findings, semaglutide could become an important tool in the fight against addiction. It may not work for everyone or for every type of addiction. But for some, it might be the extra help needed to stay in recovery.
What Are the Proposed Neurological Effects of Semaglutide Relevant to Substance Use Disorders?
Semaglutide is mostly known for helping people manage blood sugar and lose weight. But it also has effects on the brain that may help treat substance use disorders (SUDs). Scientists are now studying how semaglutide affects brain regions and chemicals involved in addiction. The goal is to learn if semaglutide can reduce cravings, lower the risk of relapse, and change how the brain responds to drugs or alcohol.
How Semaglutide Affects Brain Regions
Semaglutide works by copying the action of a natural hormone called GLP-1 (glucagon-like peptide-1). This hormone is made in both the gut and the brain. It plays a role in hunger, fullness, and blood sugar control. However, GLP-1 also affects certain brain areas that control reward and pleasure. These areas are important in addiction.
One of these areas is the nucleus accumbens, a part of the brain that responds to things that feel good—like food, alcohol, or drugs. When someone uses an addictive substance, this part of the brain becomes very active. It releases chemicals that make the person feel pleasure. Over time, this can lead to cravings and compulsive behavior.
Studies in animals show that semaglutide can reduce activity in the nucleus accumbens. This may help explain why semaglutide has been found to lower drug-seeking behavior in lab tests. If the brain doesn’t react as strongly to the substance, the person may feel fewer cravings.
Another important area is the ventral tegmental area (VTA). This is where many of the brain’s dopamine neurons are located. Dopamine is a chemical that plays a big role in motivation, pleasure, and learning. When someone uses drugs, dopamine levels in the brain spike. This sends a strong signal to the brain to repeat the behavior.
Semaglutide seems to reduce the release of dopamine in response to drugs. In animal studies, rats given semaglutide showed less interest in alcohol or cocaine. Researchers think this happens because semaglutide lowers the excitement in dopamine-producing areas like the VTA.
The prefrontal cortex (PFC) is another brain region involved in decision-making, self-control, and long-term planning. In people with addiction, the prefrontal cortex often becomes weaker or less active. This can make it harder to resist cravings or make healthy choices.
Some studies suggest that GLP-1 receptor agonists like semaglutide may improve function in the prefrontal cortex. If semaglutide helps this part of the brain work better, it could make it easier for people to stay in recovery and avoid relapse.
Dopamine and Reward Signaling
Dopamine is a key brain chemical in addiction. Many drugs and even alcohol cause a large increase in dopamine, especially in the brain’s reward centers. This is what creates a “high” and leads to repeated use.
Semaglutide may lower this dopamine response. It does not block dopamine completely, but it seems to reduce the brain’s excitement in response to addictive substances. This can make drugs or alcohol feel less rewarding, which may help reduce cravings or relapse.
Unlike traditional addiction medications that directly block or mimic other brain chemicals, semaglutide works more indirectly. It helps the brain and body work together to manage appetite, reward, and self-control. This approach could be useful for people who struggle with both addiction and overeating or emotional eating.
Neuroinflammation and Brain Health
Substance use can cause neuroinflammation, which means swelling and damage in the brain. This can lead to memory problems, mood issues, and poor decision-making. Over time, it also affects how the brain processes rewards and responds to stress.
Semaglutide may help reduce inflammation in the brain. Animal studies show that GLP-1 can protect brain cells and lower inflammation. This could be important for people in recovery, as it may help the brain heal from past damage caused by drugs or alcohol.
Semaglutide may also support neuroprotection, which means protecting nerve cells from damage. In some studies, GLP-1 receptor agonists have shown benefits in brain diseases like Alzheimer’s and Parkinson’s. These same protective effects might help people recovering from addiction regain brain function over time.
Connecting Metabolism and Brain Behavior
Addiction and metabolism are closely linked. People with substance use disorders often have problems with appetite, weight, and blood sugar. These problems may affect brain chemistry, making cravings and mood swings worse.
By helping control blood sugar and appetite, semaglutide may also improve mental health and emotional balance. This makes it easier to focus on recovery and avoid relapse triggers.
More research is needed to fully understand how semaglutide works in the brain. But early findings show promise. Semaglutide affects brain areas involved in reward, reduces dopamine spikes from drugs, and may help protect the brain from damage. These effects suggest it could be a helpful tool for treating substance use disorders in the future.
Are There Ongoing Clinical Trials on Semaglutide for Substance Use Disorders?
Semaglutide is best known for helping people with type 2 diabetes and obesity. But now, scientists are studying it for a very different reason — to see if it can help people with substance use disorders (SUDs). SUDs include addictions to alcohol, nicotine, opioids, and other drugs. Early research in animals showed that semaglutide may affect the brain’s reward system. This is the same system involved in addiction. Because of this, researchers started clinical trials in people to learn more.
Clinical trials are studies that test how safe and effective a treatment is in humans. Some are small and focus on safety. Others are larger and look at whether the treatment really works. Right now, there are several clinical trials looking at how semaglutide might help people with different types of addictions. These trials are in various stages. Some are still recruiting volunteers. Others are already testing results.
One of the main areas of research is alcohol use disorder (AUD). In 2023, the National Institute on Drug Abuse (NIDA) and other research groups started funding studies to test semaglutide in people who struggle with alcohol. One clinical trial is being run at the University of North Carolina. It’s testing whether semaglutide can reduce alcohol cravings and drinking behaviors. The people in the study are either given semaglutide or a placebo (a fake treatment), and their drinking habits are tracked over time. This type of study is called a randomized, placebo-controlled trial. It is considered the gold standard for medical research because it helps show if the drug really works.
Other trials are looking at nicotine dependence. In one study, researchers are testing whether semaglutide can help people quit smoking. The idea is that semaglutide may reduce the urge to smoke by calming the brain’s reward system. If people feel less pleasure from smoking, they may be more likely to stop. This could be a new way to help people quit, especially if they have tried other methods without success.
There is also interest in opioid use disorder. Though no large human trials have finished yet, researchers are planning or preparing studies to test semaglutide with opioids. In animal studies, semaglutide reduced drug-seeking behavior for opioids. These results are encouraging, but scientists need to confirm them in humans. Before that happens, safety studies are needed to make sure semaglutide won’t cause harm when used with people in recovery from opioid addiction.
Most of these clinical trials are also looking at how semaglutide changes behavior and brain activity. Some use brain scans to see if certain areas of the brain become less active when exposed to triggers, like pictures of alcohol or drugs. Others use questionnaires to measure cravings, stress levels, or emotional changes. Some studies are measuring relapse rates, meaning how often someone starts using drugs or alcohol again after a period of recovery. These are important tools to understand whether semaglutide helps reduce the risk of relapse.
Another key part of these trials is understanding how long semaglutide should be used. Researchers want to know if it only helps short-term or if it can support people in recovery over many months. They are also tracking side effects, especially in people who already have health problems linked to long-term substance use, such as liver disease or mental health conditions.
Because this is a new area of research, many of the results are not yet available. Some trials may take months or years to complete. But early findings are promising. A few small studies have shown that semaglutide can reduce cravings or lower the desire to use alcohol. However, scientists stress that more research is needed before it can be widely used for addiction treatment.
In the future, semaglutide may become a useful tool in treating substance use disorders. But for now, researchers are still working to understand exactly how it works, how safe it is, and how it fits with other treatments like therapy and support groups. Clinical trials will give us those answers. As more results are published, doctors and scientists will be better able to decide whether semaglutide can truly help people recover from addiction.
What Are the Risks and Limitations of Using Semaglutide in SUD Treatment?
Semaglutide is getting a lot of attention for its possible role in treating substance use disorders (SUDs). While the early research is exciting, it’s important to understand the risks and limits of using this medication in people who struggle with addiction. Even though semaglutide is already used to treat type 2 diabetes and obesity, using it for addiction is still very new. Doctors and researchers are working to learn more before it becomes a regular part of treatment for SUDs.
Known Side Effects of Semaglutide
Semaglutide can cause side effects, especially in the stomach and digestive system. Many people taking semaglutide feel nausea, vomiting, diarrhea, or constipation, especially in the first few weeks. These symptoms often go away over time, but for some people, they can be hard to deal with and may cause them to stop using the drug.
In rare cases, semaglutide can lead to more serious health problems. These include:
- Pancreatitis (swelling of the pancreas), which causes stomach pain that doesn’t go away
- Gallbladder problems, including gallstones
- Low blood sugar when used with other diabetes medications
People with certain health conditions may face more risk. For example, semaglutide is not recommended for people who have had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2, because of a possible link to thyroid tumors.
These side effects are already known from the use of semaglutide for diabetes and weight loss. But people with substance use disorders may have other medical conditions or use other drugs, which could increase the chances of serious side effects.
Behavioral and Mental Health Concerns
People in recovery from addiction often have mental health challenges, such as depression, anxiety, or trauma. Some researchers are asking if semaglutide could affect mood or mental state in ways that are not yet known. Since semaglutide works in the brain as well as the body, it could change how people feel or think.
So far, no major mental health side effects have been reported in the studies about semaglutide and weight loss. Still, addiction and recovery can make people more sensitive to changes in brain chemistry. For that reason, researchers are watching closely for any signs of mood changes or mental health problems when semaglutide is used in this group.
Also, semaglutide might change how people feel about rewards or cravings. This could help reduce drug-seeking behavior. But it could also affect how people enjoy food, relationships, or other healthy rewards. Scientists need more research to know if semaglutide could lower interest in all rewards, not just drugs.
Gaps in Long-Term Data
One big challenge is the lack of long-term data. Most semaglutide studies have followed people for just a few months to one year. Addiction is a lifelong condition, and people may need support for many years. It’s not clear yet if semaglutide will keep working over the long term to reduce drug use or cravings.
Also, no one knows what happens when a person stops taking semaglutide. Do cravings come back? Does the person lose any progress they made? These questions are important before doctors can feel confident using semaglutide to treat SUDs.
Animal Studies Don’t Always Match Human Results
Much of the early research on semaglutide and addiction has been done in animal models, mostly rats and mice. These studies are helpful, but animals and humans are different. A drug that works in rats may not work the same way in people. Human brain chemistry is more complex, and people have emotions, habits, and social influences that animals do not.
Only a few small studies have been done in humans so far, and many of them are still ongoing. It’s too soon to say for sure that semaglutide will help people with addiction in the same way it helped animals.
Who Might Not Be a Good Fit for Semaglutide?
Semaglutide may not be right for everyone. People who are underweight, have eating disorders, or struggle with nutrition may not do well with a drug that lowers appetite. Others may already be taking medicines that interact with semaglutide, making it harder to manage side effects or risks.
People with a history of uncontrolled mental illness, liver problems, or multiple medications may also need careful monitoring. Right now, doctors don’t have enough guidelines for using semaglutide in people with complex medical or psychiatric histories.
Moving Forward With Caution
While semaglutide could be a helpful tool for addiction treatment, much more research is needed. Doctors must carefully weigh the benefits against the risks for each person. Semaglutide is not a cure and is not yet approved for use in treating substance use disorders. As studies continue, researchers hope to learn who will benefit the most, how to reduce side effects, and how to use the drug safely and effectively in recovery settings.
Could Semaglutide Support Weight and Metabolic Recovery in SUD Patients?
People recovering from substance use disorders (SUDs) often face more than just cravings or withdrawal. Many also struggle with weight gain, changes in appetite, and long-term problems with metabolism. These issues can make recovery harder and increase the risk of relapse. That’s where semaglutide may have a helpful role. Even though semaglutide was first used for type 2 diabetes and weight loss, researchers are now looking at how it might also help with the physical health of people in recovery from addiction.
Why Metabolic Health Matters in Addiction Recovery
Substance use affects the brain, but it also harms the body. Long-term use of drugs or alcohol can change how the body handles food, stores fat, and uses energy. For example, people who use stimulants like cocaine or methamphetamine may lose a lot of weight during use. When they stop using, they often gain weight quickly. Alcohol use can damage the liver and lead to problems with blood sugar and fat levels. Opioids can slow digestion and change how the body stores fat.
Poor nutrition and weight changes during recovery can make people feel tired, sick, or uncomfortable in their bodies. This can affect their mental health and make them more likely to return to drug or alcohol use. For people in recovery, gaining control over their physical health can be just as important as treating addiction itself.
Semaglutide’s Role in Supporting Metabolic Recovery
Semaglutide works by copying a hormone in the body called GLP-1 (glucagon-like peptide-1). This hormone helps control blood sugar, reduces hunger, and makes people feel full sooner. Because of these effects, semaglutide helps people lose weight in a slow, steady, and healthy way.
For people in recovery from SUDs, this could have many benefits. Weight gain after quitting drugs is very common, especially in people who stop using stimulants or nicotine. This sudden weight gain can lead to high blood sugar, increased body fat, and even type 2 diabetes. Semaglutide may help manage these issues by lowering appetite and improving how the body handles sugar and fat.
Some studies show that semaglutide can lower blood pressure, improve cholesterol levels, and reduce liver fat. These are common problems in people with alcohol use disorder or those who had poor diets while using drugs. By improving these markers, semaglutide could help people feel better physically, which might support their mental health too.
The Link Between Physical and Mental Recovery
When people feel physically unwell, it’s harder to focus on therapy or stay motivated in recovery. Fatigue, poor sleep, and low energy are all common problems that can be made worse by weight gain or poor nutrition. By helping the body return to a healthier state, semaglutide may make recovery smoother and more sustainable.
There’s also growing research showing that physical and mental health are closely connected. Improving one area can often lead to improvements in the other. For example, better blood sugar control and weight loss have been linked to lower depression and anxiety in some people. These are common mental health concerns for those recovering from addiction.
Potential Use as a Dual-Benefit Treatment
Because semaglutide can help both the brain and the body, it may one day be part of a “dual-benefit” treatment plan. That means it could help with cravings and reward behaviors in the brain while also helping people manage their weight and metabolic health. Some researchers believe this could lead to better long-term results in recovery.
For example, someone recovering from alcohol use disorder might take semaglutide to help reduce their cravings and also to protect their liver and manage their weight. A person who recently quit smoking might use it to avoid gaining weight and to stay motivated as they build new healthy habits. These ideas are still being studied, but they show how semaglutide could be more than just a weight loss drug.
A New Tool for Recovery Care
As researchers learn more, semaglutide may become part of a broader approach to treating SUDs—one that focuses on both the mind and the body. Helping people recover their physical health can give them more energy, confidence, and stability. That can make it easier to stay in treatment, attend therapy, and avoid relapse.
While semaglutide is not yet approved for use in treating addiction, early research shows promise. It may help reduce health risks linked to substance use and improve quality of life during recovery. For people working hard to rebuild their lives, support for both physical and mental health is key—and semaglutide might be one way to offer that support.
How Does Semaglutide Compare to Current Medications for Addiction?
Doctors use several medications to help people with substance use disorders. These drugs can help reduce cravings, lower the chance of relapse, and make withdrawal symptoms easier to manage. Some of the most common medications include naltrexone, buprenorphine, methadone, and acamprosate. Each one works in a different way. Now, researchers are looking at semaglutide to see if it could also help people recover from addiction. Understanding how semaglutide is different—and possibly useful—means comparing it to the treatments we already have.
Different Ways of Working in the Brain
The biggest difference between semaglutide and most addiction medicines is how they affect the brain.
Medications like naltrexone and acamprosate are used for alcohol use disorder. Naltrexone works by blocking opioid receptors in the brain. These receptors play a role in how we feel pleasure and rewards. When naltrexone blocks them, alcohol may not feel as rewarding. This can make it easier for people to stop drinking. Acamprosate, on the other hand, helps calm brain activity. It is believed to restore the chemical balance in the brain that gets disrupted by long-term alcohol use.
For people with opioid use disorder, doctors often prescribe methadone or buprenorphine. These drugs are called opioid agonists or partial agonists. They bind to the same receptors as opioids like heroin or fentanyl, but in a slower, more controlled way. This can prevent withdrawal symptoms and reduce cravings without creating the same strong “high.” Methadone is a full agonist and buprenorphine is a partial one, which means buprenorphine has a lower risk of overdose.
Semaglutide does not work like any of these drugs. It is a GLP-1 receptor agonist, which means it mimics a hormone called glucagon-like peptide-1. This hormone helps regulate appetite, blood sugar, and insulin levels. But it also has effects in the brain, especially in areas involved with reward and motivation. These are the same brain areas affected by addictive drugs. Early studies suggest that semaglutide may lower cravings or reduce interest in drugs like alcohol, nicotine, and opioids by affecting how the brain responds to rewards.
Not a Replacement, But Possibly an Add-On
Because semaglutide works differently, researchers are not trying to replace current treatments right away. Instead, they are looking at whether semaglutide could be used together with other medications. This is sometimes called adjunct therapy. For example, someone might take buprenorphine to manage withdrawal and cravings and also take semaglutide to reduce their interest in food or drug rewards.
This dual approach might help people who have both substance use disorder and health problems like obesity or type 2 diabetes, which are common in recovery. Treating both problems at the same time may improve a person’s overall health and their chances of long-term recovery.
What About Behavior Therapies?
Most treatment plans for addiction include behavioral therapy, such as counseling or group therapy. These treatments help people understand why they use substances and teach them how to avoid relapse. Semaglutide does not replace this kind of help, but it could support it. If a person feels fewer cravings, they may be more likely to stay in therapy and follow through with recovery steps.
Some researchers think semaglutide might improve self-control by acting on parts of the brain that help with decision-making. This could make it easier for people to make healthy choices and avoid risky behavior.
Still Early, But Worth Watching
There are still many questions about semaglutide’s role in treating addiction. It is not yet approved for this purpose, and studies are still ongoing. But its unique way of working makes it an interesting option. Instead of acting on the brain’s opioid system, like most current medications, semaglutide may change how the brain sees rewards in general. This could open new doors for people who do not respond well to existing treatments.
For now, semaglutide is not meant to replace proven addiction treatments. But it may become part of a new type of treatment that looks at both the body and the brain. Doctors and researchers are watching closely to see how this medication might fit into future recovery plans.
Ethical and Regulatory Considerations in Repurposing Semaglutide
As researchers explore the potential use of semaglutide for treating substance use disorders, it’s important to think about the ethical and regulatory issues that come with this new direction. Semaglutide is already approved for managing type 2 diabetes and obesity, but using it for addiction treatment is not yet approved by the U.S. Food and Drug Administration (FDA). This means that doctors and scientists must move carefully when considering its use for a completely different condition.
Off-Label Use and Vulnerable Populations
Doctors sometimes prescribe medications “off-label.” This means they use an FDA-approved drug to treat a condition it wasn’t originally approved for. While off-label use is legal, it carries risks, especially for vulnerable groups like people with substance use disorders. These patients may already be dealing with physical health problems, mental health challenges, and social barriers like poverty or lack of access to care.
Prescribing semaglutide off-label to someone recovering from addiction may help, but it can also raise questions. Does the patient fully understand the risks and benefits? Could they feel pressured to take a medication that is still being studied for their condition? People with addiction are sometimes treated unfairly or judged by the healthcare system. That’s why it’s especially important to protect their rights and make sure they are treated with respect, honesty, and fairness.
The Role of the FDA and Drug Approval Pathways
Before semaglutide can be widely used for addiction treatment, it would need to go through the FDA’s drug approval process for this new use. That means completing large, well-designed clinical trials to prove the drug is safe and effective for substance use disorders.
There are two main pathways for this kind of drug development. One is to go through a full approval process from scratch, which takes years and costs a lot of money. The other is to repurpose the drug by building on the existing safety data already collected for its approved uses. This is called drug repurposing or repositioning. It can be faster, but it still requires strong evidence, especially when the new use involves the brain and behavior.
Even though semaglutide has passed safety tests for diabetes and obesity, those studies may not cover everything related to people with addiction. For example, researchers will need to study how semaglutide affects cravings, relapse, mood, and overall mental health. They will also need to look at how it interacts with other medications used in addiction treatment, such as methadone or buprenorphine.
Cost and Access Issues
Semaglutide is currently an expensive medication. It may cost several hundred to over a thousand dollars per month without insurance. Even with insurance, not all plans cover it fully. If research supports using semaglutide for addiction, cost will become a major issue.
Many people with substance use disorders face financial difficulties. They may not have insurance or regular access to healthcare. If semaglutide becomes part of treatment, steps will need to be taken to make sure it’s affordable and available to the people who need it most.
In addition, doctors and clinics that treat addiction may not be used to prescribing diabetes or obesity medications. Training and guidance will be needed so they can use semaglutide safely and properly.
Prescribing for Non-Metabolic Use
Semaglutide’s effects on weight loss and blood sugar are well known. But when used for substance use disorder, the goal is different. The focus is on reducing cravings and helping the brain recover from addiction. Some people may start taking semaglutide for addiction treatment and then lose a lot of weight, even if they were not overweight to begin with. This raises ethical questions. Could people misuse the drug for weight loss if it’s prescribed for addiction? How do doctors balance the physical effects with the mental and behavioral goals?
Healthcare providers must carefully explain why semaglutide is being used and what the expected outcomes are. Patients should give informed consent, which means they fully understand the reasons for the treatment and the possible side effects. Shared decision-making between doctors and patients is essential.
Moving Toward Responsible Use
As the science moves forward, researchers, regulators, and healthcare professionals must work together. They need to make sure that the use of semaglutide for substance use disorders is backed by strong evidence, clear rules, and fair access for all patients. Ethical care includes protecting patient rights, being transparent, and making sure treatments are safe and based on good science.
Regulatory decisions should also include voices from addiction experts, primary care providers, and patients themselves. That way, the final choices reflect real needs and real-world situations.
Semaglutide may offer a promising new tool in addiction recovery, but its use must be guided by careful planning and strong ethical standards. The goal is to improve lives—not just with new treatments, but with better systems of care.
Conclusion: The Future of GLP-1 in Addiction Medicine
Semaglutide is a medication that was first made to help people with type 2 diabetes. It also became popular for helping people lose weight. But in recent years, scientists have started to notice something new about this drug. They have found that semaglutide may also affect the brain in ways that could help people who struggle with addiction. This includes people who are addicted to alcohol, opioids, nicotine, and other drugs. Because of this, researchers are now looking more closely at how semaglutide might be used to treat substance use disorders, or SUDs.
We now know that semaglutide is a type of drug called a GLP-1 receptor agonist. That means it acts like a natural hormone in the body called GLP-1. This hormone helps control blood sugar, makes people feel full, and may also affect how the brain feels pleasure and reward. These brain effects are very important when it comes to addiction. Drugs and alcohol can change the brain’s reward system, making people crave substances even when they want to stop. Semaglutide seems to reduce some of this craving in animal studies. It may do this by lowering dopamine activity in key parts of the brain that are involved in addiction.
Many animal studies have shown that GLP-1 drugs like semaglutide can reduce the desire for alcohol, cocaine, opioids, and nicotine. In these studies, rats or mice given semaglutide were less likely to seek out the drug. Some even stopped pressing levers to get the drug at all. This suggests that semaglutide may reduce drug-seeking behavior. A few early human studies are also being done. While the research in humans is still limited, the early signs are promising. People in some of these studies reported having less interest in alcohol or other substances while taking semaglutide. However, much more research is needed before doctors can be sure that it works safely for this purpose.
Another interesting finding is that semaglutide may help with more than just cravings. People who struggle with addiction often have other health problems too. These can include obesity, type 2 diabetes, and heart disease. These problems can make recovery harder. Semaglutide can help with these health issues by lowering blood sugar, reducing body weight, and improving heart health. This means it might support recovery by improving both mental and physical health at the same time.
Still, there are important safety questions. Like all medications, semaglutide can have side effects. These can include nausea, vomiting, diarrhea, and sometimes more serious problems like pancreatitis. People with substance use disorders may already have sensitive health situations, so careful testing is needed. Right now, semaglutide is not approved to treat addiction. Any use in this area would be considered “off-label,” which means it is not yet backed by official guidelines. Doctors and researchers must be cautious and follow strict rules when testing it for new uses.
If semaglutide is found to work for addiction, it will likely not replace current treatments. Medications like buprenorphine for opioid use disorder or naltrexone for alcohol use disorder have proven success. Instead, semaglutide could be used alongside these treatments. It might work well with therapy, support groups, or other medications. This could help create a more complete treatment plan. It could also offer a new option for people who don’t respond well to current treatments.
In the future, we may see more studies looking at how semaglutide affects the brain’s reward system. These studies may help us understand how food, drugs, and habits are linked in the brain. This could lead to new ways to treat both addiction and obesity—two conditions that often happen together. It may also open the door for other GLP-1 drugs to be studied in the same way.
In summary, semaglutide shows promise as a possible new tool in addiction treatment. It affects the brain’s reward system and may help lower cravings. It also supports physical health, which is often an important part of recovery. However, we are still in the early stages. We need more studies in humans to understand how well it works, who it helps most, and what side effects may happen. As science moves forward, semaglutide may become a useful part of addiction medicine. But for now, it remains a hopeful area of research, not yet a standard treatment.
Research Citations
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C., Koob, G. F., Roberto, M., Vendruscolo, L. F., & Leggio, L. (2023). The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight, 8(12), e170671. https://doi.org/10.1172/jci.insight.170671
Klein, K., Vendruscolo, L. F., Leggio, L., et al. (2024). Once‐weekly semaglutide in adults with alcohol use disorder: A phase 2 randomized controlled trial. JAMA Psychiatry. Advance online publication. https://doi.org/10.1001/jamapsychiatry.2024.4789
Xie, Y., et al. (2024). Association of semaglutide with reduced incidence and relapse of alcohol use disorder in real‐world populations: A retrospective cohort study. Nature Communications, 15, 1234. https://doi.org/10.1038/s41467-024-48780-6
Quddos, F., Hubshman, Z., Tegge, A., et al. (2023). Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports, 13, 20998. https://doi.org/10.1038/s41598-023-48267-2
Marty, V. N., Farokhnia, M., Munier, J., et al. (2020). Long‐acting glucagon‐like peptide‐1 receptor agonists suppress voluntary alcohol intake in male Wistar rats. Frontiers in Neuroscience, 14, 599646. https://doi.org/10.3389/fnins.2020.599646
Vallöf, D., Kalafateli, A. L., & Jerlhag, E. (2016). The glucagon‐like peptide‐1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addiction Biology, 21(3), 422–437. https://doi.org/10.1111/adb.12215
Kostantinis, G., Klein, K., Powell, M., et al. (2024, May). Evaluating safety and tolerability of semaglutide in participants with substance use disorder [Poster presentation]. In American Society of Clinical Psychopharmacology Annual Meeting.
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., et al. (2023). Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats. EBioMedicine, 93, 104642. https://doi.org/10.1016/j.ebiom.2023.104642
O’Brien, E. (2024). Efficacy of semaglutide for the treatment of substance use disorders. Psychiatric Times. Retrieved from https://www.psychiatrictimes.com/view/efficacy-of-semaglutide-for-the-treatment-of-substance-use-disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink-Jensen, A. (2022). The role of glucagon-like peptide-1 (GLP-1) in addictive disorders. British Journal of Pharmacology, 179(1), 625–641. https://doi.org/10.1111/bph.15500
Questions and Answers: Semaglutide and Substance Abuse Disorders
Semaglutide is a GLP-1 receptor agonist used primarily to treat type 2 diabetes and obesity. It helps regulate blood sugar and reduce appetite.
Early research suggests semaglutide may reduce cravings and addictive behaviors, possibly by affecting brain reward pathways linked to dopamine and impulse control.
No, semaglutide is not currently FDA-approved for treating any substance use disorder. Its use in this area is still under investigation.
Research has looked at semaglutide’s potential effects on alcohol, nicotine, cocaine, and opioid use disorders, though most data are preclinical or from small trials.
Semaglutide may influence brain areas like the nucleus accumbens and prefrontal cortex, decreasing reward sensitivity and impulse-driven behaviors related to substance use.
A few early-phase clinical trials are ongoing or recently completed, focusing on semaglutide’s effects on alcohol and nicotine cravings, but results are still emerging.
There’s limited data, but semaglutide does not appear to have significant interactions with these medications. However, more research is needed for confirmation.
Common side effects include nausea, vomiting, diarrhea, and appetite suppression. In people with SUDs, these effects may complicate nutritional status or medication adherence.
Possibly. Many individuals in recovery struggle with weight gain, especially after quitting substances like alcohol or nicotine. Semaglutide might help manage this.
Ethical concerns include access, cost, potential misuse for weight loss rather than addiction, and the need for more robust evidence before wide adoption in addiction care.
Dr. Judith Germaine
Dr. Jude (Germaine-Munoz) Germaine, MD is a family physician in Springfield, New Jersey. She is currently licensed to practice medicine in New Jersey, New York, and Florida. She is affiliated with Saint Josephs Wayne Hospital.